Merck & Co Inc
MRK
Company Profile
Business description
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
Contact
126 East Lincoln Avenue
RahwayNJ07065
USAT: +1 908 740-4000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
75,000
Merck & Co Inc News & Analysis
stocks
A wave of US biotech IPOs may be starting - here’s why
M&A activity is bolstering IPOs within key areas of the biotech space. A GLP-1 maker and a protein biomarker detection company are the latest.
markets
Market Minute: Trade policy dominates, opportunities in global healthcare, and a local rate cut on the cards
Senior Portfolio Manager Bryce Anderson reviews the biggest market movements of the week, with Trump’s trade policy dominating again.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,062.40 | 2.90 | 0.03% |
| CAC 40 | 8,437.89 | 74.75 | 0.89% |
| DAX 40 | 25,155.41 | 144.06 | 0.58% |
| Dow JONES (US) | 52,218.58 | 6.06 | -0.01% |
| FTSE 100 | 10,716.97 | 131.06 | 1.24% |
| HKSE | 25,129.11 | 236.45 | 0.95% |
| NASDAQ | 25,690.90 | 146.30 | -0.57% |
| Nikkei 225 | 66,419.37 | 303.77 | 0.46% |
| NZX 50 Index | 13,755.81 | 7.37 | -0.05% |
| S&P 500 | 7,498.96 | 10.24 | -0.14% |
| S&P/ASX 200 | 8,881.70 | 4.10 | 0.05% |
| SSE Composite Index | 3,867.10 | 0.06 | 0.00% |